within Pharmacolibrary.Drugs.N_NervousSystem.N02B_OtherAnalgesicsAndAntipyretics.N02BA07_Ethenzamide;

model Ethenzamide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.7,
    Cl = 2.777777777777778e-06,
    adminDuration = 600,
    adminMass = 250 / 1000000,
    adminCount = 1,
    Vd = 0.0009,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ethenzamide</td></tr><tr><td>ATC code:</td><td>N02BA07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>250</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>10</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ethenzamide is a non-opioid analgesic and antipyretic drug historically used for relief of pain and fever. It acts primarily by inhibiting the synthesis of prostaglandins. The drug has been used mainly in Japan and several other countries, often in combination with caffeine and acetaminophen. It is not widely used or approved in many countries today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adults after a single oral dose, as no published human compartmental PK models are available.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N02BA07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ethenzamide;
